Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-22-010397
Filing Date
2022-02-01
Accepted
2022-02-01 17:06:44
Documents
1
Period of Report
2022-01-31

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm225088-4_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm225088-4_4seq1.xml 4 5961
  Complete submission text file 0001104659-22-010397.txt   7672
Mailing Address C/O ACHILLION PHARMACEUTICALS, INC. 300 GEORGE STREET NEW HAVEN CT 06511
Business Address
VAN NOSTRAND ROBERT L (Reporting) CIK: 0001225198 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33958 | Film No.: 22579799

Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Issuer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations